Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Neoplasms 9Prostatic Neoplasms 6Multiple Myeloma 6Fractures, Bone 4Neoplasm Metastasis 3Giant Cell Tumor of Bone 3Carcinoma, Non-Small-Cell Lung 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Parathyroid Neoplasms 2Osteoporosis 2Lymphoma 2Thyroid Neoplasms 1Smoldering Multiple Myeloma 1Recurrence 1Paraproteinemias 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplastic Processes 1Neoplastic Cells, Circulating 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Hyperparathyroidism, Primary 1Hypercalcemia 1

Interventions

Carboplatin 23Cisplatin 19pembrolizumab 14Paclitaxel 12Gemcitabine 12Pemetrexed 11130-nm albumin-bound paclitaxel 9Everolimus 8Cetuximab 8Fluorouracil 7Axitinib 6osimertinib 5durvalumab 5Sunitinib 5Radiotherapy 5Erlotinib Hydrochloride 5Docetaxel 5Cyclophosphamide 5Albumin-Bound Paclitaxel 5Sorafenib 4Radiation 4Nivolumab 4Ipilimumab 4vosaroxin 3Radiotherapy, Intensity-Modulated 3Octreotide 3Irinotecan 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3pralsetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma × Denosumab × Clear all
NCT00838201 2018-10-18

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Amgen

Phase 3 Completed
384 enrolled 8 charts
Genitourinary

Carcinoma, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡